Screening of Beta-Secretase Inhibitors by Capillary Electrophoresis-Mass Spectrometry
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
- Keywords
- Alzheimer’s disease, Beta-secretase, Capillary electrophoresis, Enzyme inhibition, Mass spectrometry, Screening,
- MeSH
- Alzheimer Disease drug therapy metabolism MeSH
- Amyloid beta-Protein Precursor metabolism MeSH
- Aspartic Acid Endopeptidases metabolism MeSH
- Electrophoresis, Capillary methods MeSH
- Mass Spectrometry methods MeSH
- Enzyme Inhibitors pharmacology MeSH
- Protease Inhibitors pharmacology MeSH
- Kinetics MeSH
- Humans MeSH
- Mass Screening methods MeSH
- Amyloid Precursor Protein Secretases antagonists & inhibitors MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Amyloid beta-Protein Precursor MeSH
- Aspartic Acid Endopeptidases MeSH
- Enzyme Inhibitors MeSH
- Protease Inhibitors MeSH
- Amyloid Precursor Protein Secretases MeSH
Alzheimer's disease is the most common cause of dementia, currently afflicting almost 40 million patients worldwide. According to the amyloid cascade hypothesis, the pathogenesis of the disease could be slowed down or even stopped by the inhibition of beta-secretase, making this aspartic acid protease a potentially important drug target site. Capillary electrophoresis is a promising technique for screening putative enzyme inhibitors due to highly effective separations, minuscule sample and other chemicals consumption, compatibility with a variety of detection techniques, and high throughput via automation. This chapter presents a method based on capillary electrophoresis coupled to mass spectrometry detection for kinetic and inhibition assays of the beta-secretase reaction with a decapeptide derived from an amyloid precursor protein.
References provided by Crossref.org
